<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H0B2FF510CCDE40C3A196B39DE3821643" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2368 IH: Right to Try Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-05-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2368</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170504">May 4, 2017</action-date><action-desc><sponsor name-id="F000466">Mr. Fitzpatrick</sponsor> (for himself, <cosponsor name-id="S001191">Ms. Sinema</cosponsor>, and <cosponsor name-id="B001302">Mr. Biggs</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To authorize the use of experimental drugs, biological products, and devices by patients diagnosed with a terminal illness in accordance with State law, and for other purposes.</official-title></form><legis-body id="HFA19BE03658F4BFFA92DDB21A6A5A902" style="OLC"> 
<section id="H386784543C73418A9F320EAFBBF2ED78" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Right to Try Act</short-title></quote>.</text></section> <section id="HAAFADEC912B54956A85D657A5F14AE66" section-type="subsequent-section"><enum>2.</enum><header>Use of unapproved medical products by patients diagnosed with a terminal illness</header> <subsection id="HE3D568F745374513928DC7AA22C01AFC"><enum>(a)</enum><header>In general</header><text>Notwithstanding the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301</external-xref> et seq.), the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801</external-xref> et seq.), and any other provision of Federal law, the Federal Government shall not take any action to prohibit or restrict—</text> 
<paragraph id="H3599F15056944DB5B86FA212B8820616"><enum>(1)</enum><text>the production, manufacture, distribution, prescribing, or dispensing of an experimental drug, biological product, or device that—</text> <subparagraph id="H10716CBC1D304C93AF2BE02CC436F060"><enum>(A)</enum><text>is intended to treat a patient who has been diagnosed with a terminal illness; and</text></subparagraph> 
<subparagraph id="HD46FC30C089440C29EAAE2B4794100DB"><enum>(B)</enum><text>is authorized by, and in accordance with, State law; and</text></subparagraph></paragraph> <paragraph id="H3AD124EABB6F484EA46161EA54FDC9E0"><enum>(2)</enum><text>the possession or use of an experimental drug, biological product, or device—</text> 
<subparagraph id="HF2F9433E83FD45D2A4F7B1B9AE18BC3B"><enum>(A)</enum><text>that is described in subparagraphs (A) and (B) of paragraph (1); and</text></subparagraph> <subparagraph id="H84E6C888A72F47ED8FBD4D9E2860A6DB"><enum>(B)</enum><text>for which the patient has received a certification from the patient’s treating physician in accordance with subsection (b).</text></subparagraph></paragraph></subsection> 
<subsection id="H488B8FEE2AFC4F659C5DBF2D2BB44224"><enum>(b)</enum><header>Physician certification</header><text>A certification by the patient’s treating physician referred to in subsection (a)(2)(B) must include each of the following:</text> <paragraph id="H06320F06717648B7934F7C1C47289B0F"><enum>(1)</enum><text>A certification that the physician—</text> 
<subparagraph id="HD658F08A04444BA98EC69FC1CA7C57D3"><enum>(A)</enum><text>is in good standing with the physician’s certifying organization or board; and</text></subparagraph> <subparagraph id="H9BE6D5C1AC6B4DD3AC54ECF69CAEEEBC"><enum>(B)</enum><text>has personally examined the patient.</text></subparagraph></paragraph> 
<paragraph id="H1ABB976604B240D2B37EDEDC6A618DF9"><enum>(2)</enum><text display-inline="yes-display-inline">A certification that there is no reason to conclude the experimental drug, biological product, or device poses an unreasonable and significant risk of danger to the patient.</text></paragraph> <paragraph id="H340C13EEC6DF47A68C33C3293054DE1C"><enum>(3)</enum><text>A certification that the patient has been diagnosed with a terminal disease or condition and does not have any treatment options that—</text> 
<subparagraph id="H2D17377A1EBE4458BF7F3D5D45DB03D3"><enum>(A)</enum><text display-inline="yes-display-inline">are comparable to treatment using the experimental drug, biological product, or device or otherwise satisfactory; and</text></subparagraph> <subparagraph id="HF201D9FE88264BF793E5EF1C4948E3CE"><enum>(B)</enum><text display-inline="yes-display-inline">are approved, licensed, or cleared for commercial distribution under section 505, 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), 360(e)) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) and are available to diagnose, monitor, or treat the patient’s disease or condition.</text></subparagraph></paragraph> 
<paragraph id="H107EF03D61D54C5A80FCBCFB5E8121CF"><enum>(4)</enum><text display-inline="yes-display-inline">A certification that the probable risk to the patient from the experimental drug, biological product, or device is not greater than the probable risk from the patient’s disease or condition.</text></paragraph> <paragraph id="HB9EE275B14AB4327A7461D0DB0D40281"><enum>(5)</enum><text>A certification that the physician has provided the patient with a written statement and oral explanation of the medical treatment to be provided using the experimental drug, biological product, or device.</text></paragraph> 
<paragraph id="HC8CD752E04264EBBA040FBE83017E1EB"><enum>(6)</enum><text>An acknowledgement signed by the patient (or the patient’s legal representative) that the physician has provided the written statement and oral explanation required by paragraph (5), and has disclosed the following:</text> <subparagraph id="H910A1FFA8B124BEB9E22A9533850A8FD"><enum>(A)</enum><text display-inline="yes-display-inline">That the medical treatment using the experimental drug, biological product, or device is experimental or nonconventional.</text></subparagraph> 
<subparagraph id="H6DD2DB3A2A8041E8A253276F436EF4EA"><enum>(B)</enum><text display-inline="yes-display-inline">That the experimental drug, biological product, or device has not been approved, licensed, or cleared for commercial distribution under section 505, 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), 360(e)) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) for any indication.</text></subparagraph> <subparagraph id="H6A46DF1660BE43CAAE2F4E0A8661FE07"><enum>(C)</enum><text display-inline="yes-display-inline">The material risks generally recognized by a reasonably prudent physician of the medical treatment’s side effects.</text></subparagraph> 
<subparagraph id="HE634C83F40D24469A999827450660327"><enum>(D)</enum><text>An explanation of the medical treatment, including the expected frequency and duration of the treatment. </text></subparagraph></paragraph></subsection> <subsection id="H1B720C6F5DCD49E4A50BDA9065A4508A"><enum>(c)</enum><header>No liability or use of outcomes</header> <paragraph id="HE3D5E0208EA143749E930E37A04E194D"><enum>(1)</enum><header>No liability</header><text>Notwithstanding any other provision of law, no liability shall lie against a producer, manufacturer, distributor, prescriber, dispenser, possessor, or user of an experimental drug, biological product, or device for the production, manufacture, distribution, prescribing, dispensing, possession, or use of an experimental drug, biological product, or device that is in compliance, with subsection (a).</text></paragraph> 
<paragraph id="H80195A81EAA64A21A8BC9C276D6F0257"><enum>(2)</enum><header>No use of outcomes</header><text>Notwithstanding any other provision of law, the outcome of any production, manufacture, distribution, prescribing, dispensing, possession, or use of an experimental drug, biological product, or device that was done in compliance with subsection (a) shall not be used by a Federal agency reviewing the experimental drug, biological product, or device to delay or otherwise adversely impact review or approval of such experimental drug, biological product, or device.</text></paragraph></subsection> <subsection id="HAC68E772B4284001BE9EC67554D58FD4"><enum>(d)</enum><header>Rules of construction</header><text>Nothing in this Act shall be construed to—</text> 
<paragraph id="HB87DA82B5473404EA07A13EEB3A7779C"><enum>(1)</enum><text display-inline="yes-display-inline">require a manufacturer or other person to make available any experimental drug, biological product, or device; or</text></paragraph> <paragraph id="H8F2A56A8EFB74CA797016A5493AA1360"><enum>(2)</enum><text>prohibit a manufacturer or other person from receiving compensation or recovering costs for the production, manufacture, distribution, or sale of an experiment drug, biological product, or device.</text></paragraph></subsection> 
<subsection id="H6478ED2B169C423FA7F99969932DC518"><enum>(e)</enum><header>Definitions</header><text>In this section:</text> <paragraph id="H5D8B982ECD204C6CB5A00579D1AC5023"><enum>(1)</enum><header>Biological product</header><text>The term <term>biological product</term> has the meaning given to such term in section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text></paragraph> 
<paragraph id="H12DE4464088247A089B5A35F87ADA1CA"><enum>(2)</enum><header>Device; drug</header><text>The terms <term>device</term> and <term>drug</term> have the meanings given to such terms in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>).</text></paragraph> <paragraph id="HE5982D2753FF446C9649385E0A3DF516"><enum>(3)</enum><header>Experimental drug, biological product, or device</header><text>The term <term>experimental drug, biological product, or device</term> means a drug, biological product, or device that—</text> 
<subparagraph id="H2934963D1FBC45FBA1F2DDB237AB3EEF"><enum>(A)</enum><text>has successfully completed a phase 1 clinical investigation;</text></subparagraph> <subparagraph id="HC6D2D09465AC4E1388BAF7A56A993E96"><enum>(B)</enum><text>remains under investigation in a clinical trial approved by the Food and Drug Administration; and</text></subparagraph> 
<subparagraph id="HE0688454DFCE4B2FB4D5F45C4C26D4E9"><enum>(C)</enum><text>is not approved, licensed, or cleared for commercial distribution under section 505, 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), 360(e)) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text></subparagraph></paragraph> <paragraph id="H3B374C8C9B854627BEBAB6A5A8CA1CB6"><enum>(4)</enum><header>Phase 1 clinical investigation</header><text>The term <term>phase 1 clinical investigation</term> means a phase 1 clinical investigation, as described in section 312.21 of title 21, Code of Federal Regulations (or any successor regulations).</text></paragraph> 
<paragraph id="H4BBD533E53224789865841955DB5989E"><enum>(5)</enum><header>Terminal illness</header><text>The term <term>terminal illness</term> has the meaning given to such term in the State law specified in subsection (a)(1)(B).</text></paragraph></subsection></section> </legis-body></bill>

